Analysis of the p53 gene in human choriocarcinoma cell lines

Abstract

SummaryIn the present study. we analysed human choriocarcinoma cell lines for abnormalities in the tumour-suppressor gene p53 by Southern blotting, Northern blotting, non-radioisotopic single-stranded conformational polymorphism (SSCP) and complementary DNA sequencing. In all cell lines (Bewo, GCH-1, GCH-2. SCH, JAR, JEG-3. NUC-1 and HCCM-5), no p53 gene abnormality was detected by using Southern blotting. p53 mRNA of the expected size was detected in all cell lines tested by Northern blotting. SSCP analysis revealed abnormalities of p53 cDNA in the SCH cell line. Sequencing analysis of the entire coding region of the p53 gene revealed that both alleles were expressed in the JEG-3 cell line, and one of the alleles contained a point mutation (G to T) in codon 167 (Gln to His). In the NUC-1 cell line both alleles were point mutated. One allele had a point mutation (A to T) that resulted in a codon 17 change (Glu to Asp), and another had a point mutation (A to T) that caused a codon 24 change (Lys to Asn). In the SCH cell line, AGG was inserted between codon 249 and 250; this insertion resulted in an abnormal structure of the p53 protein. In three out of eight human choriocarcinoma cell lines, a p53 gene abnormality was detected. Therefore our data demonstrate that p53 gene abnormalities are associated with choriocarcinoma cell lines.

Regulation of Hypoxia-inducible Factor 1α (HIF-1α) by Lysophosphatidic Acid Is Dependent on Interplay between p53 and Krüppel-like Factor 5

“…Consistently, LPA induces HIF-1␣ and VEGF expression in SK-Hep1 cells with wtp53 but not in p53-null Hep-3b cells (41,42). On the other hand, it is reported that LPA stimulated HIF-1␣ expression in ovarian OVCAR-3 and CAVOV-3 cells, despite the presence of mutp53 (41,43). The basis for the differential cellular responses by the different cell types is not known.…”

Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models

“…33 PA -1 ovarian tumor cells carry a silent mutation and are p53 wild -type. 31 MIAPaCa2 pancreatic tumor cells carry an Arg-to -Trp mutation in codon 248 of the p53 gene, an Arg -to -His mutation in codon 273 of the p53 gene, and express mutant p53. 32 …”

A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin

“…We observed that Ad-p53 22/23 failed to induce apoptosis in the Caov-3 cell line, but induced limited apoptosis in MDAH 2774 cell line (data not shown). Both ovarian cancer cell lines harbour p53 mutations (Yaginuma and Westphal, 1992). Therefore, p53 22/23 may still be able to induce apoptosis via a transcriptionindependent mechanism(s).…”